Emergent BioSolutions stock gains 14.4 percent on contract news

Published on 10/07/2026 at 03:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Emergent BioSolutions stock drew a Hold consensus on October 5, with a USD 10.00 average target. Q2 revenue reached USD 234.3 million, while full-year guidance fell to USD 645-675 million.

EBS, US29089Q1058, Illustration mit AI erstellt.

Emergent BioSolutions (ISIN US29089Q1058) stock was last at USD 7.24 on the NYSE on October 6 after a 14.4 percent session gain. According to Yahoo Finance on October 6, investors responded to new biodefense contracts, a Canadian government offer and debt reduction.

Contracts lift biodefense demand

The reported catalyst was a USD 24 million BARDA contract modification for Cyfendus, Emergent's anthrax preparedness product. The company also won a three-year Canadian government standing offer to supply NARCAN nasal spray, extending its public-sector reach.

The same report said Emergent repurchased USD 75 million of debt at a discount. That combination gives the stock a direct operating catalyst and a balance-sheet angle, although the commercial naloxone business remains central to the next earnings debate.

Q2 revenue rises as loss widens

According to StockTitan, Q2 2026 revenue reached USD 234.3 million, up from USD 140.9 million in Q2 2025. Adjusted EBITDA increased to USD 96.5 million from USD 33.1 million, but GAAP net loss was USD 180.2 million, including a USD 191.3 million impairment.

The company cut full-year 2026 revenue guidance to USD 645-675 million from USD 720-760 million. Adjusted EBITDA guidance also fell to USD 130-150 million from USD 155-175 million, while Q3 revenue guidance stands at USD 110-130 million.

Consensus target stays above price

MarketBeat reported on October 5 that six analysts carry a consensus Hold rating, split between two Sell, one Hold and three Buy recommendations. The average 12-month price target is USD 10.00, which lies 38.1 percent above the USD 7.24 reference price.

The consensus therefore reflects a divided view: the target implies upside from the October 6 quote, while the guidance reduction and the impairment show why the commercial outlook remains the key counterweight.

Stock remains below yearly high

EBS was last at USD 7.24 on the NYSE on October 6, with a market capitalization of USD 358.6 million and a 52-week range of USD 4.36 to USD 14.06. The next earnings date listed for the company is October 28, 2026.